Holen Sie sich die Stockscreener-App
9.09
6.58%
-0.64
Handel nachbörslich:
9.14
0.05
+0.55%
Schlusskurs vom Vortag:
$9.73
Offen:
$9.73
24-Stunden-Volumen:
1.08M
Relative Volume:
0.87
Marktkapitalisierung:
$593.80M
Einnahmen:
$141.31M
Nettoeinkommen (Verlust:
$-297.87M
KGV:
-1.6854
EPS:
-5.3933
Netto-Cashflow:
$-168.20M
1W Leistung:
-12.60%
1M Leistung:
+14.48%
6M Leistung:
-1.62%
1J Leistung:
-15.76%
1-Tages-Spanne:
$8.84
$9.805
1-Wochen-Bereich:
$8.75
$10.58
52-Wochen-Spanne:
$5.37
$17.58
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Firmenname
Ginkgo Bioworks Holdings Inc
Sektor
Branche
Telefon
(877) 442-5362
Adresse
27 DRYDOCK AVENUE, BOSTON
Compare DNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
9.09 | 593.80M | 141.31M | -297.87M | -168.20M | -5.3933 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-15 | Herabstufung | BTIG Research | Neutral → Sell |
| 2024-05-10 | Herabstufung | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-06-02 | Herabstufung | Goldman | Neutral → Sell |
| 2023-05-11 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | Eingeleitet | Berenberg | Buy |
| 2022-10-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2022-02-23 | Eingeleitet | Goldman | Neutral |
| 2022-02-01 | Eingeleitet | BofA Securities | Neutral |
| 2022-01-28 | Eingeleitet | BofA Securities | Buy |
| 2022-01-07 | Eingeleitet | BTIG Research | Buy |
| 2021-11-29 | Eingeleitet | Jefferies | Buy |
| 2021-10-13 | Eingeleitet | Raymond James | Outperform |
| 2021-10-12 | Eingeleitet | William Blair | Outperform |
| 2021-09-20 | Eingeleitet | HSBC Securities | Buy |
Alle ansehen
Ginkgo Bioworks Holdings Inc Aktie (DNA) Neueste Nachrichten
Ginkgo Bioworks Holdings' Stock Sinks To US$9.07, But Insiders Sold Even Lower - simplywall.st
Ginkgo Bioworks : Q1 2026 Results Presentation - marketscreener.com
DNAGinkgo Bioworks Holdings Inc Options - Finviz
Ginkgo Bioworks reports Q1 revenue decline, reaffirms cash burn - Investing.com
Earnings call transcript: Ginkgo Bioworks Q1 2026 sees revenue drop, restructuring efforts noted - Investing.com
ETFs Investing in Ginkgo Bioworks Holdings, Inc. Class A Stocks - TradingView
Most Volatile Stocks in the US (July 2026) - Investing.com
Ginkgo Bioworks Holdings Inc Warrant 2021-01.08.26 on Ginkgo Bioworks -A Financial Disclosures & SEC Filings - TradingView
Ginkgo Bioworks (DNA) Holds Near $10.21 as Stock Consolidates in Tight RangeIron Condor Alert - dars.gov.et
Ginkgo Bioworks Holdings, Inc.(NYSE:DNA) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Ginkgo Bioworks Holdings, Inc.(NYSE: DNA) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Ginkgo Bioworks Holdings, Inc.(NYSE:DNA) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Palantir's Bold Biosecurity Opportunity Could Be Bigger Than Investors Think - The Motley Fool
Ginkgo Bioworks (DNA) Q1 2026 Earnings: EPS Misses Estimates, Stock Surges Over 7%Buyback Announcement Report - dars.gov.et
Enterprise value to revenue forward of Ginkgo Bioworks Holdings, Inc. – NYSE:DNA - TradingView
Price to earnings forward of Ginkgo Bioworks Holdings, Inc. – NYSE:DNA - TradingView
Enterprise value to EBIT forward of Ginkgo Bioworks Holdings, Inc. – NYSE:DNA - TradingView
Enterprise value to EBITDA forward of Ginkgo Bioworks Holdings, Inc. – NYSE:DNA - TradingView
Price to sales forward of Ginkgo Bioworks Holdings, Inc. – NYSE:DNA - TradingView
Ginkgo Bioworks (DNA) Rallies 6.27% as Biotech Sector Shows Renewed StrengthInitial Balance - dars.gov.et
Ginkgo Bioworks Holdings, Inc. Class A Actuals & Estimates (NYSE:DNA) - TradingView
9L40 Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Ginkgo Bioworks Holdings Inc. – OTC:DNABW - TradingView
Price to earnings forward of Ginkgo Bioworks Holdings Inc. – OTC:DNABW - TradingView
Enterprise value to EBITDA forward of Ginkgo Bioworks Holdings Inc. – OTC:DNABW - TradingView
Price to book forward of Ginkgo Bioworks Holdings Inc. – OTC:DNABW - TradingView
DNA Forecast — Price Target — Prediction for 2027 - TradingView
Ginkgo Bioworks Holdings Inc (DNA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
The Technical Signals Behind (DNA) That Institutions Follow - Stock Traders Daily
DNA Technical Analysis & Stock Price Forecast - Intellectia AI
Ginkgo Bioworks Holdings Inc (DNA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Institutional Confidence - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ginkgo Bioworks Holdings Inc - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ginkgo Bioworks (DNA) director Henry Christian O receives 25,000 RSU equity grant - Stock Titan
Director Ross Fubini receives 25,000 RSUs at Ginkgo Bioworks (NYSE: DNA) - Stock Titan
Director at Ginkgo Bioworks (NYSE: DNA) granted 25,000 RSUs - Stock Titan
Ginkgo Bioworks (DNA) director Harry Sloan awarded 25,000 RSUs - Stock Titan
Ginkgo Bioworks Holdings, Inc. Files Form 8-K With SEC for June 2026 – Key Submission Details and Company Information 17 – Minichart - Minichart
Ginkgo Bioworks Shareholders Back Board, Governance Structure - The Globe and Mail
Ginkgo Bioworks (NYSE: DNA) shareholders approve directors, Deloitte and executive pay - Stock Titan
Austin Che (DNA) files Form 144 showing sales totaling tens of thousands of Class A shares - Stock Titan
Precision Trading with Ginkgo Bioworks Holdings Inc. Class A (DNA) Risk Zones - Stock Traders Daily
Ginkgo Bioworks (DNA) Holds Steady Near Support as Trading Volume Remains SubduedEntry Point Alerts - dars.gov.et
Ginkgo Bioworks Holdings, Inc. - MLQ.ai
Top Ginkgo Bioworks (DNA) Competitors 2026 - MarketBeat
Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Ginkgo Bioworks Holdings, Inc. of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Significant Losses to Contact the Firm - TMX Newsfile
Finanzdaten der Ginkgo Bioworks Holdings Inc-Aktie (DNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):